腹膜假黏液瘤39例临床分析

Peritoneal pseudomyxoma: A clinical analysis of 39 cases

  • 摘要: 目的 探讨腹膜假性黏液瘤的临床特点及术后并发症相关危险因素。 方法 收集我院2002-2011年收治的39例腹膜假黏液瘤患者的临床数据,回顾性分析术后并发症的发生情况和预后影响因素。 结果 39例中,17例出现术后并发症,并发症发生率为43%,主要并发症有腹腔内感染及肠梗阻。25例术后复发,中位复发时间12个月。美国东部肿瘤协作组(Eastem Cooperative Oncology Group,ECOG)评分≥1发生术后并发症的风险增加(P<0.05)。性别、年龄、手术时间及术后是否行腹腔内热化疗对术后并发症发生风险无统计学意义。单因素及多因素分析显示病理分型为弥散性腹膜黏液腺瘤病及治疗方式为手术联合热化疗对推迟术后复发时间有统计学意义(P<0.05)。 结论 对于ECOG评分≥1的患者应谨慎选择手术并应预防术后并发症的发生。病理分型为弥散性腹膜黏液腺瘤病的患者术后联合腹腔内热化疗可推迟术后复发时间。

     

    Abstract: Objective To study the clinical characteristics of peritoneal pseudomyxoma and the relative risk factors for its postoperative complications. Methods Thirty-nine peritoneal pseudomyxoma patients admitted to our hospital from 2002 to 2011 were included in this study.Their clinical data, including its postoperative complications and its prognosis-inf luencing factors were retrospectively analyzed. Results Of the 39 patients, 17 (43%) developed complications after operation such as intestinal obstruction and intra-abdominal infection, 25 had recurrence with a median recurrence time of 12 months.The risk to develop complications after operation increased when the ECOG score was ≥1 (P< 0.05).No signif icant difference was observed in gender, age, operation time and hyperthermic intraperitoneal chemotherapy (HIPEC) among the patients (P> 0.05).Univariate and multivariate analyses showed that the peritoneal pseudomyxoma was pathologically typed as disseminated peritoneal adenomueinosis(DPAM).Operation in combination with HIPEC could delay its recurrence (P< 0.05). Conclusion Postoperative complications of peritoneal pseudomyxoma should be prevented in patients with their ECOG score ≥1.Operation in combination with HIPEC can delay the recurrence of DPAM.

     

/

返回文章
返回